WINSTON-SALEM, N.C. — January 6, 2026 — Leads & Copy — ProKidney Corp. (Nasdaq: PROK), a clinical-stage cell therapy company focused on chronic kidney disease (CKD), announced that CEO Bruce Culleton, M.D., will present at the 44th Annual J.P. Morgan Healthcare Conference.
The ProKidney management team will also host one-on-one meetings throughout the event. The conference presentation details are:
Date: Wednesday, January 14, 2026
Time: 8:15am PST
Format: Presentation
Webcast: Link
The live webcast will be accessible through the “Events” section of the Investor Relations tab within ProKidney’s website. A replay will be available for 30 days following the event.
ProKidney, founded in 2015 after a decade of research, focuses on treating CKD through innovations in cell therapy. ProKidney’s lead product candidate, rilparencel (also known as REACT®), is a first-in-class, patented, proprietary autologous cell therapy with regenerative medicine advanced therapy designation. It is being evaluated in the ongoing Phase 3 REGEN-006 (PROACT 1) study for its potential to preserve kidney function in patients with advanced CKD and type 2 diabetes.
ProKidney Contact:
Ethan Holdaway
Ethan.Holdaway@prokidney.com
Media Contact:
Audra Friis
audrafriis@sambrown.com
Investor Relations Contact:
Daniel Ferry
Daniel@lifesciadvisors.com
Source: ProKidney Corp.
